CAMIDANLUMAB TESIRINE
UNII LYJ1AEJ9YH

Substance Identification & Data

This profile provides standardized clinical and technical data for Camidanlumab Tesirine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LYJ1AEJ9YH.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1853239-04-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LYJ1AEJ9YH

CAS Registry Number

1853239-04-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CAMIDANLUMAB TESIRINE

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C121949

National Cancer Institute reference terminology for clinical and research data.

INN ID

10592

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FG-27

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Camidanlumab Tesirine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CAMIDANLUMAB TESIRINE

Common Names & Synonyms

CAMIDANLUMAB TESIRINE [INN]

CAMIDANLUMAB TESIRINE [USAN]

CAMIDANLUMAB TESIRINE [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 2 RECEPTOR .ALPHA. CHAIN)(HUMAN HUMAX-TAC HEAVY CHAIN), HUMAN HUMAX-TAC LIGHT CHAIN, DIMER, THIOETHER WITH N-(31-(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1-YL)-1,29-DIOXO-4,7,10,13,16,19,22,25-OCTAOXA-28-AZAHENTRIACONT-1-YL)-L-VALYL-N-(4-(((((11S,11AS)-8-((5-(((11AS)-5,11A-DIHYDRO-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-8-YL)OXY)PENTYL)OXY)-11,11A-DIHYDRO-11-HYDROXY-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPINE-10(5H)-YL)CARBONYL)OXY)METHYL)PHENYL)-L-ALANINAMIDE

SYS

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS INTERLEUKIN-2 RECEPTOR SUBUNIT ALPHA (TAC ANTIGEN, P55, CD25 ANTIGEN)), HOMO SAPIENS MONOCLONAL ANTIBODY CONJUGATED TO AN AVERAGE OF TWO MOLECULES OF TESIRINE.GAMMA.1 HEAVY CHAIN (1-445) (HOMO SAPIENS VH (IGHV1-69*02 (95%) (IGHD)-IGHJ4*01 (93%)) (8.8.8) (1-115) -HOMO SAPIENS IGHG1*03 (116-445)), (218-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-214') (HOMO SAPIENS V-KAPPA (IGKV3-20*01 (99%) IGKJ4*01)(6.3.9) (1'-107') -HOMO SAPIENS IGKC*01 (108'-214'))DIMER (224-224'':227-227'')-BISDISULFIDE, AN AVERAGE OF TWO CYSTEINES ARE S-LINKED TO (111AS,911S,911AS,16S,19S,523RS)-911-HYDROXY-17, 97-DIMETHOXY-12,92,16-TRIMETHYL-15,95,10,15,18,21,49,522-525-NONAOXO-19-(PROPAN-2-YL)-15,111A,911,911A-TETRAHYDRO-11H,91H,95H-2,8,11,24,27,30,33,36,39,42,45-UNDECAOXA-14,17,20,48-TETRAAZA-1(8),9(8,10)-BIS(PYRROLO(2,1-C)(1,4)BENZODIAZEPINE)-52(1)-PYRROLIDINA-13(1,4)BENZENADOPENTACONTAPHAN-523-YL

SYS